{"generic":"Dextran","drugs":["Dextran"],"mono":{"0":{"id":"3prks0","title":"Generic Names","mono":"Dextran"},"1":{"id":"3prks1","title":"Dosing and Indications","sub":[{"id":"3prks1b4","title":"Adult Dosing","mono":"<ul><li><b>Complication of procedure - Hysteroscopy - Uterine distension:<\/b> (intrauterine with hysteroscopy) instill through hysteroscope cannula under low pressure (approximately 100 mm Hg) but enough to keep cavity suitably distended; do not exceed 150 mm Hg to avoid injection of fluid into tissues or leaking into the peritoneal cavity<\/li><li><b>Dextran adverse reaction; Prophylaxis:<\/b> Note: Promit(R) (dextran 1) is no longer available in the U.S.: 20 mL IV rapid infusion 1 to 2 min before the IV infusion of clinical dextran solutions<\/li><li><b>Extracorporeal circulation procedure, Pump primer; Adjunct:<\/b> dose varies with volume of pump oxygenator; generally, LMD 10% solution (1 to 2 g) 10 to 20 mL\/kg body weight; MAX total dose not to exceed 2 g\/kg of body weight<\/li><li><b>Plasma expander transfusion; Adjunct - Traumatic shock:<\/b> 10% dextran 40, initial dose 10 mL\/kg IV, infused as rapidly as necessary to effect improvement, MAX dose 20 mL\/kg in first 24 h; beyond 24 h, daily dose should not exceed 10 mL\/kg\/day, therapy should not exceed 5 days<\/li><li><b>Thromboembolic disorder, In procedures with high incidence of thromboembolic complications; Prophylaxis:<\/b> 10% dextran 40, 500 to 1000 mL (10 mL\/kg of body weight) IV on day of surgery, then 500 mL daily for 2 to 3 days; depending on risk of complications, may give 500 mL every second or third day during period of risk for up to 2 wks<\/li><\/ul>"},{"id":"3prks1b5","title":"Pediatric Dosing","mono":"<ul><li><b>Extracorporeal circulation procedure, Pump primer; Adjunct:<\/b> infants, 10% dextran 40, 5 mL\/kg of body weight IV<\/li><li><b>Extracorporeal circulation procedure, Pump primer; Adjunct:<\/b> adolescents, dose varies with volume of pump oxygenator; generally, LMD 10% solution (1 to 2 g) 10 to 20 mL\/kg body weight; MAX total dose not to exceed 2 g\/kg of body weight<\/li><li><b>Plasma expander transfusion; Adjunct - Traumatic shock:<\/b> infants, 10% dextran 40, 5 mL\/kg of body weight IV<\/li><li><b>Plasma expander transfusion; Adjunct - Traumatic shock:<\/b> adolescents, 10% dextran 40, initial dose 10 mL\/kg IV, infused as rapidly as necessary to effect improvement, MAX 20 mL\/kg in first 24 hr; beyond 24 hr, MAX 10 mL\/kg\/day, for no more than 5 days<\/li><li><b>Plasma expander transfusion; Adjunct - Traumatic shock:<\/b> 6% dextran 70, up to 20 mL\/kg<\/li><li><b>Thromboembolic disorder, In procedures with high incidence of thromboembolic complications; Prophylaxis:<\/b> adolescents, 10% dextran 40, 500 to 1000 mL (10 mL\/kg of body weight) IV on day of surgery, then 500 mL daily for 2 to 3 days; depending on risk of complications, may give 500 mL every second or third day during period of risk for up to 2 wks<\/li><li><b>Thromboembolic disorder, In procedures with high incidence of thromboembolic complications; Prophylaxis:<\/b> infants, 10% dextran 40, 5 mL\/kg of body weight IV<\/li><\/ul>"},{"id":"3prks1b6","title":"Dose Adjustments","mono":"<b>renal impairment:<\/b> reduce dose"},{"id":"3prks1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Complication of procedure - Hysteroscopy - Uterine distension<\/li><li>Dextran adverse reaction; Prophylaxis<\/li><li>Extracorporeal circulation procedure, Pump primer; Adjunct<\/li><li>Plasma expander transfusion; Adjunct - Traumatic shock<\/li><li>Thromboembolic disorder, In procedures with high incidence of thromboembolic complications; Prophylaxis<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><br\/>Transplant of lung, Lung preservation<br\/>"}]},"3":{"id":"3prks3","title":"Contraindications\/Warnings","sub":[{"id":"3prks3b9","title":"Contraindications","mono":"<ul><li>hypersensitivity to dextran or corn products<\/li><li>pulmonary edema<\/li><li>renal disease with severe oliguria or anuria<\/li><li>severe bleeding disorders<\/li><li>severe congestive heart failure<\/li><\/ul>"},{"id":"3prks3b10","title":"Precautions","mono":"<ul><li>bowel surgery<\/li><li>decreased urinary output secondary to shock<\/li><li>dehydration<\/li><li>hemorrhage, active<\/li><li>hypernatremia (with products containing sodium chloride)<\/li><li>pathological abdominal conditions<\/li><li>thrombocytopenia<\/li><\/ul>"},{"id":"3prks3b11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"3prks3b12","title":"Breast Feeding","mono":"<ul><li>WHO: Compatible with breastfeeding.<\/li><li>Micromedex: Infant risk cannot be ruled out.<\/li><\/ul>"}]},"4":{"id":"3prks4","title":"Drug Interactions","sub":{"1":{"id":"3prks4b14","title":"Major","mono":"<ul><li>Abciximab (probable)<\/li><li>Heparin (theoretical)<\/li><li>Tinzaparin (theoretical)<\/li><\/ul>"}}},"5":{"id":"3prks5","title":"Adverse Effects","mono":"<b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Congestive heart failure<\/li><li><b>Hematologic:<\/b>Thrombocytopenia<\/li><li><b>Immunologic:<\/b>Anaphylaxis<\/li><li><b>Renal:<\/b>Acute renal failure<\/li><li><b>Respiratory:<\/b>Pulmonary edema<\/li><\/ul>"},"6":{"id":"3prks6","title":"Drug Name Info","sub":{"2":{"id":"3prks6b19","title":"Class","mono":"Volume Expander<br\/>"},"3":{"id":"3prks6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"3prks6b21","title":"Generic Availability","mono":"Yes<br\/>"}}},"9":{"id":"3prks9","title":"Administration","mono":"<ul><li><b>Intrauterine<\/b><br\/><ul><li>(intrauterine with hysteroscopy) instill through hysteroscope cannula under low pressure (approximately 100 mm Hg) but enough to keep cavity suitably distended; do not exceed 150 mm Hg to avoid injection of fluid into tissues or leaking into the peritoneal cavity<\/li><li>heat at 100 to 110 degrees C if crystallization flakes are present (until complete dissolution)<\/li><\/ul><\/li><li><b>Intravenous<\/b><br\/><ul><li>(Dextran 40) give IV infusion only<\/li><li>(Dextran 40) prediluted in 500 mL of NS or D5; when infusing concentrated solution, use a filter<\/li><\/ul><\/li><\/ul>"},"10":{"id":"3prks10","title":"Monitoring","mono":"<ul><li>central venous pressure during initial infusion<\/li><li>observe for bleeding complications<\/li><li>urine output<\/li><li>hysteroscopy: signs of pulmonary edema, intravascular volume expansion (especially if procedure time &gt; 45 min)<\/li><\/ul>"},"11":{"id":"3prks11","title":"How Supplied","mono":"<b>Generic<\/b><br\/>Intravenous Solution: 32 %<br\/>"},"13":{"id":"3prks13","title":"Clinical Teaching","mono":"Instruct patient to report signs\/symptoms of bleeding complications, pulmonary edema, congestive heart failure, or renal failure.<br\/>"}}}